Science
A potent antibiotic has emerged in the battle against deadly, drug-resistant superbugs
Under a microscope, this drug-resistant superbug looks as benign as a handful of pebbles. Yet carbapenem-resistant Acinetobacter baumannii, or CRAB, is a nightmare for hospitals worldwide, as it kills roughly half of all patients who acquire it.
Identified as a top-priority pathogen by both the World Health Organization and the U.S. Centers for Disease Control and Prevention, CRAB is the most common form of a group of bacteria that are resistant to nearly all available antibiotics. Victims are typically hospitalized patients who are already sick with blood infections or pneumonia. In the U.S. alone, the bug sickens thousands and kills hundreds every year.
But 2024 is starting with some encouraging news on the global health front: For the first time in half a century, researchers have identified a new antibiotic that appears to effectively kill A. baumannii.
The compound, zosurabalpin, attacks bacteria from a novel angle, disrupting the route that a key toxin takes on its journey from inside the bacterial cell to the outer membrane that shields the bug from the immune system’s defensive onslaughts.
No other antibiotic approved by the U.S. Food and Drug Administration takes this approach, and the element of surprise is an important advantage against even microscopic foes. A. baumannii has had no opportunity to develop resistance against the drug, which means that, for at least a little while, zosurabalpin could ward off severe illness and death.
“As far as I can tell, the scientific approach is brilliant,” said Dr. Oladele A. Ogunseitan, a professor of population health and disease prevention at UC Irvine who was not involved with the study.
The drug was developed jointly by scientists at the Swiss pharmaceutical company Roche and at Harvard University. Their findings were published Wednesday in the journal Nature.
Carbapenem-resistant A. baumannii is a type of Gram-negative bacteria, a vexing category of superbugs. Encased in both an inner and outer membrane that antibiotics struggle to cross, Gram-negative bacteria are resistant to most currently available therapies. They are also astonishingly canny for unicellular organisms, with the ability to rapidly develop new defenses against antibiotics and then pass them along to other bacteria through genetic material.
Antibiotic-resistant superbugs claim the lives of more than 1 million people globally each year. The rise of drug resistance is due in part to human folly — we have long over-prescribed and misused antibiotics — but it is also because bacteria are continually finding ways to evade threats. Over the last 50 years, these pathogens have evolved defenses faster than we can produce new drugs.
In their search for a new weapon, the Roche and Harvard scientists turned their attention to a group of compounds called tethered macrocyclic peptides. After testing a library of 45,000 MCPs, the researchers came across one that seemed especially lethal against A. baumannii. After some chemical tinkering, that compound became zosurabalpin.
“This is a very promising advance,” said Paul J. Hergenrother, a chemistry professor at the University of Illinois who was not involved in the research but wrote of the findings for Nature. “Zosurabalpin kills bacteria in a way that is different from all other approved antibiotics.”
The drug kicks into gear only in the presence of lipopolysaccharide, a bacterial toxin. LPS is made inside the bacterial cell and is carried by a dedicated transport system to the bug’s outer defenses.
“The bacterial outer membrane is important for bacteria because it helps them to live in harsh conditions and to survive attacks by our immune system,” said Kenneth Bradley, Roche’s global chief of discovery for infectious diseases.
Zosurabalpin essentially cuts off the LPS transport route. Without a way to get to the outer membrane of the cell, where it can get to work fighting off drugs and immune attacks, the toxin builds up inside the bacteria and eventually kills the cell.
In mice studies, the drug effectively killed off CRAB infections in the blood, lungs and thighs, a selection that mirrors the ways the bug infects humans.
It’s currently in Phase I trials in humans, where researchers are looking at the drug’s safety, tolerability and the amount of the chemical that remains in patients’ bodies over time, said Michael Lobritz, Roche’s infectious disease chief.
“It has been more than 50 years since the last distinct class of antibiotic was launched that is capable of treating infections by Gram-negative bacteria,” Lobritz said in an email. “Any new antibiotic class that has the ability to treat infections caused by multidrug resistant (MDR) bacteria such as carbapenem-resistant Acinetobacter baumannii (CRAB) would be a significant breakthrough.”
Encouraging as the early results are, scientists stressed that it would be foolish to get cocky in the fight against a bug that, time and time again, has found ways to evade our most advanced pharmaceutical weaponry.
“Resistance has emerged to every antibiotic ever created, and it is likely that resistance will emerge to zosurabalpin in the future too, if it successfully becomes a clinical antibiotic,” Bradley said.
In their findings, the authors noted a few gene mutations in the lab that significantly decreased the drug’s success against A. baumannii. These were rare but worrying; one freak mutation reduced the drug’s effectiveness 256-fold.
“Although the rates of appearance of these resistant organisms is low, and comparable to standard-of-care antibiotics, the observation affirms the principle that we can never rest on our laurels with the chemical and biochemical warfare that we are waging on bacterial pathogens,” Ogunseitan said.
Zosurabalpin is essentially unknown to bacteria. If it proves safe and effective in humans, there’s likely a limited window in which it could effectively spare lives and suffering. But no matter how sophisticated our tools, scientists said, these potentially deadly cells will always have a major advantage against us.
“Bacteria have a big numbers advantage — billions can be in a flask,” said Hergenrother. “Bacteria will eventually evolve resistance to virtually every antibiotic, which is why we need a steady supply of new antibiotic candidates.”
Science
After Trump axed federal employees running climate site, thousands crowdfund its comeback
Federal employees who were axed during waves of cuts by the Trump administration have fought back against the dismantling of a key climate science website, Climate.gov, and put up a new site, Climate.us, that can now do everything the original did.
The site, with millions of users each year, was known for colorful charts that anyone could freely download and that simplified giant sets of data, such as temperature readings. Now it refers to another page and is no longer being updated.
Daniel Swain, a UC Agriculture & Natural Resources climate scientist, called the resources available at Climate.gov “the most efficacious dollars spent by NOAA on public-facing science, possibly ever.” He has used graphics from the former website on his popular weather blog.
“I am a terrible artist or illustrator. It would be very bad if I had to create those on my own.” Swain said. The website didn’t just make graphics that were beautiful, he said, they were accurate and reliable because of the network of researchers who fact-checked them.
Rebecca Lindsey was the editorial lead and program manager for Climate.gov until February 2025, when her position at the National Oceanic and Atmospheric Administration was eliminated by the Elon Musk-led Department of Government Efficiency, or DOGE. She explained that the online resource was “a bridge between scientists, data and the public.”
Lindsey and her team have now rebuilt the bridge piece by piece, if just a bit further downstream.
The team is made of the same editorial and technical staff that ran Climate.gov. It’s paid for through a crowdfunding campaign and one large, anonymous donation.
The group has raised some $380,000, about $100,000 of which came in the last week. They also have recruited 80 scientists who are willing to volunteer as subject matter experts and fact checkers. It’s enough to keep the work going through February while they seek more long-term funding.
The first iteration of Climate.us went online in 2025 to keep the last 15 years of work from the government website available. The newest version restores the full function of the previous website.
For Californians, the timing could be important.
“We’re headed for a very strong El Niño event that will have significant implications for Southern California,” Swain said. “Climate.gov and the scientists behind it did a great job walking people through the last one, and I would expect that’s the case this time as well.”
Climate.gov excelled at tapping into a pool of academic experts to explain what was happening in nearly real time. This allowed the public to see how events such as wildfire, drought or large weather patterns such as El Niño were shaping their lives when they needed the information most. Research from academic institutions, by contrast, can take years to publish results from major natural disasters.
Swain emphasized that cuts to resources that give context to hard-to-interpret data is not just a loss for the research community.
“It’s getting more and more difficult for the American public to access the science and the scientists that their tax dollars have supported for over half a century,” he said.
With the revival of Climate.us, Swain said he plans to directly use the site and its graphics to keep Californians connected to the world of climate science.
Science
This Cell Feeds, Grows and Reproduces. And It’s Manmade.
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of ingredients, the researchers have synthesized simple cells that feed, grow, reproduce and compete with one another for food. If these cells are not yet fully alive, they have most of the hallmarks of life.
“Life is not binary,” said Kate Adamala, a synthetic biologist who led the research. “That’s why I’m hesitant to call this ‘alive.’ There’s no clear line, as much as we would love it to be.”
Until now, scientists had never mastered the recipe for a cell that can perform so many functions, said John Glass, a synthetic biologist at the J. Craig Venter Institute in La Jolla, Calif., who was not involved in the study.
“It is dazzling that she has put these things all together,” he said.
Drew Endy, a synthetic biologist at Stanford University, said, “It’s a cell that was built, not born. It’s constructed, but it does what cells do.”
Dr. Adamala named her creation SpudCell, after its potato-like appearance. Rather than patent it, she and Dr. Endy are organizing a community of scientists to focus on making SpudCells more fully alive and adapting them to new kinds of experiments.
They and their colleagues have founded a nonprofit research organization that Dr. Endy estimates will spend hundreds of millions of dollars on the effort in the next decade. Hundreds of scientists are expected to join.
“We’re going to remember this moment,” said Roseanna Zia, a computational biologist at the University of Missouri who was not involved in the project.
Dr. Adamala and her colleagues posted a 190-page account of their work online. The research is under review for publication in a scientific journal.
Scientists hope synthetic cells can tell them things about life that natural cells cannot, including such basic questions as how many genes are necessary for a minimal form of life.
But synthetic cells also might someday be engineered to do things that natural cells can’t, like making new kinds of medicine or drawing large amounts of carbon dioxide from the atmosphere. In theory, engineered SpudCells might produce a vast range of proteins that natural cells cannot be coaxed to make, or even toxic chemicals like rocket fuel.
Now, “we can think about doing chemistry that we’re barely getting our heads around,” Dr. Glass said.
The trouble with life as we know it: mysterious, messy complexity. Our own DNA contains tens of thousands of genes, as well as millions of molecular switches turning those genes on and off. Scientists barely have a clue as to what many of those pieces of DNA are doing. Often a gene that they think they understand turns out to be performing other jobs than scientists expected.
One way to sidestep this intricacy is to simplify.
In the 1990s, a team led by the late biologist Craig Venter began studying a microbe that had fewer than 1,000 genes. The team, now led by Dr. Glass, went on to strip the microbe’s genome down to 525 essential genes.
In a 2016 paper, the team reported it didn’t know what a third of those genes were doing. Dr. Glass and his colleagues have spent the last decade trying to solve the puzzle, and they still can’t say what 56 of them do.
“There are still significant tasks that every cell has to do that we don’t know,” Dr. Glass said.
Other researchers tackled the problem from the opposite direction. Instead of working from the top down, they moved from the bottom up, seeking to combine lifeless molecules to produce a living cell.
Since the 1990s, several labs have bitten off small pieces of this problem. Some of them have perfected recipes to make hollow bubbles from oily molecules. Others have found ways to encapsulate simple genetic molecules inside those bubbles.
But scientists struggled to put these pieces together into more complex systems, let alone something that could be called a cell.
In recent years, Dr. Adamala took on one of the fundamental challenges: cell division. A natural cell divides with the help of proteins that lock together into a ring anchored to its inner wall. The ring winds itself tighter, pinching the cell in two.
Other proteins act like winches, moving DNA and other molecules into the forming cells, so that they have the ingredients necessary to keep living.
At first, Dr. Adamala tried building a simpler version of the natural system. But then she decided not to mimic real cells at all.
Biophysicists had found that if they stuck proteins on a membrane, they created pressure that made the membrane bend. Dr. Adamala and her team created bubbles that could snag proteins floating around them. When a bubble collected enough proteins, its surface began bending inward until it popped in two.
While the idea was simple, getting it to work in the lab required a year of experiments. “But once it works, it works,” Dr. Adamala said.
That success prompted the team to try to build a synthetic cell in its entirety.
The first step was to create a broth of the molecules necessary for a cell to operate. The recipe ultimately included about a hundred kinds of proteins and simple molecules required for crucial chemical reactions, such as making new proteins from genes.
The researchers also provided their synthetic cell with genes borrowed from a virus and the ubiquitous microbe Escherichia coli. They picked 36 genes for basic jobs like copying DNA.
After mixing these ingredients together into a soup, the scientists added the building blocks of membranes. They spontaneously joined together into bubbles, each engulfing some of the soup.
Many of these bubbles ended up encasing the right mix of genes, proteins and other molecules, and they started carrying out the chemical reactions seen in real cells.
As the new cells floated in flasks, Dr. Adamala and her colleagues added food. The cells slurped up small molecules through channels on their surfaces.
The scientists also put in small bubbles loaded with proteins and other molecules that were too big to fit through the channels. By bumping and fusing into one of these bubbles, the cell could feed on the treats inside.
As the cells fed, they grew. And in just a few hours, they were big enough to divide.
The scientists added a special protein to the flasks, which latched onto the surface of the cells and forced them to bend inward. Once the cells split in two, the pair of new cells kept growing.
Now the SpudCells grew, fed and reproduced. As it turned out, the cells even had a rudimentary ability to evolve.
Dr. Adamala and her colleagues created a mutant version that bound more tightly to the snack-filled bubbles floating around it. To test it, they created a 50-50 mixture of original and mutant SpudCells.
The cells competed for five generations for food. Eventually the mutants outnumbered the originals, suggesting that they were outcompeting the originals for food.
“That’s the shake-the-ground accomplishment here,” said Dr. Zia. Scientists will be able to put various synthetic cells in competition with one another and rapidly develop more sophisticated ones.
For all this evidence of life, SpudCell still has some major shortcomings. For starters, it can’t make the molecular factory that produces new proteins, called a ribosome. The cells can carry all the genes they need to build ribosomes, but for some reason the parts don’t come together.
For now, Dr. Adamala and her colleagues have to feed ready-made ribosomes to SpudCells. This solution has an expiration date, though: SpudCells can keep making proteins through five to 10 generations before they fail as their ribosomes become defective.
“I don’t want to say it dies, but it stops working,” Dr. Adamala said.
When Dr. Adamala showed SpudCell to Dr. Endy last year, he was so awestruck that he decided to help her found Biotic, the nonprofit organization intended to create a community of SpudCell researchers.
“I’m pouring my life’s work into this,” Dr. Endy said. One of the first tasks for Biotic will be to make it easier for other scientists to create SpudCells.
Dr. Adamala can create a fresh batch of them in her own lab in about a day. But that’s only because she has freezers full of purified proteins and an intimate understanding of each step of her recipe. Biotic expects to offer scientists easier recipes and provide the required ingredients.
Dr. Endy hopes that the open-source tools will encourage scientists to collaborate on building new kinds of SpudCells with more of the defining features of life, such as the ability to make their own ribosomes and to divide indefinitely.
“It’s completely doable,” said Dr. Glass.
Biotic researchers are already planning their first meeting, in September in Philadelphia. High on their list of priorities will be formalizing plans to safeguard this area of research.
For now, the synthetic cell can only survive a few generations on a special lab diet. But future versions may be more robust, raising the possibility that someone might someday use SpudCells unethically, perhaps even to make a weapon.
Dr. Endy argues that an open-source research community will be better prepared to prevent that from happening. “We can have these conversations now, as opposed to waiting for somebody else to do it, and then we’re just all reacting,” he said.
Dr. Endy likens SpudCells to a biological version of the Wright flyer, the crude plane that the Wright Brothers used to make the first sustained controlled flight in 1903, ushering in the age of airplanes.
“The Wright flyer flying for 12 seconds doesn’t get you a 737,” Dr. Endy said. “This is just the beginning.”
Science
After bold pledge, EPA shelves microplastics testing in U.S. drinking water
For the next five years, the Environmental Protection Agency has indicated it will not require public water utilities to test for microplastics or pharmaceuticals in drinking water, according to a proposed rule published in the Federal Register.
On Friday, the EPA submitted a list of chemicals it plans to test for under the Unregulated Contaminant Monitoring Rule, a mandatory testing program used to collect information about concerning chemicals in drinking water that could be harming human health. It did not include microplastics or pharmaceuticals.
The omissions come after announcements by EPA Administrator Lee Zeldin earlier this year that his agency was designating microplastics and pharmaceuticals priority contaminants for testing.
“This is a direct response to the concern of millions of Americans who have long demanded answers about what they and their families are drinking every day,” he said at an April news conference with Health and Human Secretary Robert F. Kennedy Jr. at EPA headquarters.
Zeldin’s announcement was seen at the time as a move to placate the increasingly disgruntled Make America Healthy Again contingent of Trump supporters.
Now the agency says it has no validated or standardized method to test for the plastic particles in drinking water, and wouldn’t be able to develop one before December, when testing is required to begin.
Among the 33 chemicals the EPA will require water utilities to test for are seven PFAS, or forever chemicals, and three pesticide residues.
It will be five years before the EPA proposes another list.
The EPA did not respond to a request for comment.
The agency noted in its proposed rule that it will collaborate with other federal agencies to “evaluate risks and exposures” of microplastics for future monitoring.
Environmentalists reacted with frustration and resignation. They pointed out that the European Union has developed methods to test for the tiny plastic particles, which have been found in people’s blood, brains and lung tissue. California has one in the works.
“The California water board has spent a lot of time and money on how to measure in drinking water,” said Judith Enck, a former EPA regional administrator and president of the anti-plastic environmental group Beyond Plastics. “EPA should give them a call.”
California was required by a 2018 state law to establish a protocol for local water utilities to test for the particles in drinking water. The state has not yet begun reporting its results, but protocols were established in 2021. Blair Robertson, a spokesman for the State Water Resources Control Board, said it’s not “a fully validated, end-to-end regulatory method” yet.
At the April meeting, Zeldin announced that he would place microplastics on what is known as the Contaminant Candidate List, which acts as a preliminary “watch list” of unregulated, priority contaminants in drinking water. Like the mandatory monitoring list, it is updated only every five years. The most recent list was published on April 2 — the day he made his announcement.
“Americans have been ignored as they sound the alarm about plastics in their drinking water,” Zeldin said during the announcement. “That ends today by placing microplastics on the contaminant candidate list for the first time ever. EPA will follow the science, will pursue answers and will hold ourselves to the highest standards to protect the health of Americans.”
There appears to be no clear association between these two lists, although the contaminant list is supposed to inform the monitoring list. Seventy-five chemicals and four chemical groups (microplastics, pharmaceuticals, PFAS chemicals, and disinfection byproducts) were listed on the 2026 contaminant list. Only seven of those chemicals were also on the proposed monitoring list (as well as seven PFAS chemicals).
When Zeldin announced microplastics as “‘a priority contaminant for regulation,’ and called it ‘a historic action on microplastics,’ he made it seem like the administration was going to take microplastics seriously,” said Mary Grant, water policy director for the environmental group Food & Water Watch.
“By not including them, they made it clear they don’t actually have plans to immediately address this crisis by getting the real-world monitoring data that we need right now to really start correcting ourselves,” she said.
Craig Davis, senior director of plastics chemistry at the American Chemistry Council — the nation’s largest trade group for chemical companies — said that while his organization supports microplastic research, it also agrees with the EPA’s decision not to include them in the monitoring list.
“National drinking water monitoring should be based on validated, standardized methods that can produce reliable and comparable data,” said Davis in a statement. He said “limited” national monitoring resources should be focused where data can produce “actionable public health information.”
The public has 60 days to comment once the plan is published in the Federal Register.
-
Health12 minutes agoWhat Is Retatrutide? Dr. Dubrow Calls It the Most Powerful Weight-Loss Drug
-
Lifestyle27 minutes agoHow World Cup fans reflect America back at us : It’s Been a Minute
-
Technology35 minutes agoApple’s entry-level MacBook Pro could be up for a redesign
-
World42 minutes agoKhamenei body in cold storage as feared Basij mobilizes ahead of historic Iran funeral
-
Politics45 minutes agoCoalition of 25 states sues Trump admin over Medicaid work rule designed to prevent fraud
-
Health50 minutes agoWest Nile virus detected in southern state as health officials warn residents about mosquitoes
-
Sports57 minutes agoUSA World Cup star Folarin Balogun receives controversial red card during Round of 32 match
-
Technology60 minutes agoA missing kitten rode under a car hood. AI brought her home